LB-102 is an orally active inhibitor of dopamine D 2, D 3, and 5-HT7 receptors, which can be used in research on schizophrenia and other psychiatric disorders [1].
References:
[1]. Wong D F, et al. PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement[J]. Neuropsychopharmacology, 2024: 1-6.
References:
[1]. Wong D F, et al. PET clinical study of novel antipsychotic LB-102 demonstrates unexpectedly prolonged dopamine receptor target engagement[J]. Neuropsychopharmacology, 2024: 1-6.
















